Liabilities

This interactive dashboard combines a liabilities grid with a 3D structural viewer.

This tool is useful for identifying and addressing liabilities in antibodies. It is particularly useful for antibody engineering and developability optimization. AbLead utilizes an internal detection engine that incorporates the comprehensive Satlawa motifs (Satlawa et al., 2024) to identify sequence-based liabilities including deamidation, isomerization, and post-translational modifications.

The Liabilities method is a great example of my core work ethic to Be Inherently Lazy. Let the system find and map liabilities, display them on a structure, select them for mutation designs, and track the designs. Doing all of this manually takes hours while this tool completes the same tasks in seconds.

Accessing the Tool

Select at least one antibody in the Project View. Go to the Analysis menu and select Liabilities. This will open the Liabilities workspace in a new tab.

This analysis gives residue-level detail of the liabilities that were detected in the sequence(s) of the antibody. The liabilities are categorized by type and severity level. The severity level is determined by the potential impact of the modification on the antibody's stability, aggregation, or PTMs. Evaluation of the severity and structure position of the liabilities is critical for determining the best strategy for engineering the antibody to improve its developability.

Select multiple entries to see them in the grid together. This allows for comparison of liabilities between different antibodies during evaluation and engineering. Selecting an entry name in the grid toggles the display of the 3D structure with liabilities highlighted. If the entry name background is light red, it means that no 3D structure is available for that entry. Toggle select liability rows to spacefill the associated residues on the 3D structure.

Engineering of strong stability violations has been shown to improve the developability of antibodies.

Stability engineering greatly improved overall biophysical properties...

... and more than doubled stable cell titer.

Developability optimization markedly improved serum half-life.

• Kerwin et al., "Framework Mutations of the 10-1074 bnAb Increase Conformational Stability, Manufacturability, and Stability While Preserving Full Neutralization Activity." Journal of Pharmaceutical Sciences (2020).
• Williams et al., "A candidate antibody drug for prevention of malaria." Nature Medicine (2024)
• Sajadi et al., "A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV." Structure (2025)

Satlawa Liabilities Table

The following table summarizes the sequence-level liabilities detected by the AbLead internal engine, based on the Satlawa et al. (2024) classification.

Name	Tag	Severity	Motif	Description
Deamidation (high)	DeAmdH	High	N[GS] in CDRs	Deamidation of Asparagine occurs in the following motifs: NG motif (Asparagine followed by Glycine) and NS motif (Asparagine followed by Serine). Such motifs are known to be associated with deamidation (type of degradation) and can result in reduced "shelf-life".
Fragmentation (high)	FragH	High	DP in CDRs	Fragmentation occurs as cleavage at the interface between Aspartate and Proline. It is an example of a common motif that is susceptible to hydrolysis in response to pH.
Isomerization	Isom	High	D[DGHST] in CDRs	Isomerization of Aspartate occurs in the following motifs: DD (Aspartate followed by Aspartate), DG motif (Aspartate followed by Glycine), DH (Aspartate followed by Histidine), DS motif (Aspartate followed by Serine) and DT (Aspartate followed by Threonine). Such motifs are known to be connected to isomerization (type of degradation) and can cause a shorter "shelf-life" of antibodies.
Missing Cys (C)	mCys	High	C not present at 23 or 104 IMGT positions	Missing Cysteine occurs as cysteine absence at IMGT 23 or 104. Certain antibody sequence regions containing unpaired cysteines may result in structural changes, surface charges, or hydrophobicity.
Extra Cys (C)	xCys	High	C present at different position than 23 or 104 IMGT positions	Extra Cysteine occurs as cysteine present at a different position than IMGT 23 or 104. Certain antibody sequence regions containing unpaired cysteines can change an antibody's structure, apparent surface charges, or hydrophobicity.
N-linked glycosylation (NXS/T, X not P)	Ngly	High	N[^P][ST] in variable fragment	N-linked glycosylation occurs as an addition of a sugar molecule. Reduced conformational stability and shorter "shelf-life" of antibody products are connected to asparagine linked glycosylation. Incidence of glycosylation in the CDRs can also directly impair antigen recognition and therefore lead to lower efficacy.
Deamidation (medium)	DeAmdM	Medium	N[AHNT] in CDRs	Occurs in the following motifs: NA (Asparagine followed by Alanine), NH (Asparagine followed by Histidine), NN (Asparagine followed by Asparagine) and NT (Asparagine followed by Threonine). This type of deamidation is less common in comparison to the NG and NS motifs.
Hydrolysis	Hydro	Medium	NP in CDRs	Hydrolysis gives rise to the DP motif as a result of the deamidation of Asparagine (N) to Aspartate (D).
Fragmentation (medium)	FragM	Medium	TS in CDRs	Occurs as pH-dependent cleavage at the Threonine-Serine interface.
Trp (W) oxidation	TrpOx	Medium	W in CDRs	Tryptophan oxidation is one of the Post-translational modifications (PTMs).
Met (M) oxidation	MetOx	Low	M in CDRs	Methionine oxidation occurs in the CDRs. Reduced binding affinity and quicker degradation of the antibody product are linked to oxidation in these particular spots.
Deamidation (low)	DeAmdL	Low	[STK]N in CDRs	Occurs in the following motifs: SN (Serine followed by Asparagine), TN (Threonine followed by Asparagine), and KN (Lysine followed by Asparagine). This type of deamidation is less common than others.

Antibody Language Model Cutoffs

AbLead incorporates three antibody-specific language models to identify anomalous residue positions: AbLang (original single-chain model), AbLang2 (paired heavy/light chain model), and IgBert (paired masked language model). These models calculate the residue likelihood difference (Δ ln(P)) between the model's preferred residue at a position and the actual residue in your sequence:

Δ ln(P) = ln(P_highest) − ln(P_actual)

A higher difference indicates a sequence position that deviates from natural antibody distributions, making it a potential stability liability. Residues with likelihood differences greater than the Severe threshold are at a high risk of causing structural instability, low expression titers, aggregation, or poor developability.

Due to differences in how these models are trained and calibrated, their significance thresholds are scaled individually:

1. AbLang (Original): Recommended cutoff is 3.0 (Medium/Yellow) and 5.0 (Severe/Red). The original single-chain model has higher variance, meaning individual outliers often reach higher values.
2. AbLang2: Recommended cutoff is 1.0 to 1.5 (Medium/Orange) and 2.0 (Severe/Red). As a paired model with germline bias correction, its probability predictions are tightly calibrated, making lower differences statistically significant. Differences above 2.0 indicate highly anomalous positions.
3. IgBert: Recommended cutoff is 1.5 to 2.0 (Medium/Orange) and 2.5 (Severe/Red). This paired masked language model has intermediate variance; differences above 2.5 indicate highly anomalous positions.

Overall Stability Score Thresholds

In addition to residue-level cutoffs, AbLead calculates overall stability scores for each antibody (Full Fv and Framework-only FR) by summing the likelihood differences. These scores are colored in the main results dashboard based on percentiles calibrated against the OAS reference database:

• AbLang Full: Green/Good ≤ 78.23, Yellow/Warning ≤ 101.82, Red/Severe > 101.82
• AbLang FR: Green/Good ≤ 39.45, Yellow/Warning ≤ 59.55, Red/Severe > 59.55
• AbLang2 Full: Green/Good ≤ 8.74, Yellow/Warning ≤ 13.11, Red/Severe > 13.11
• AbLang2 FR: Green/Good ≤ 4.58, Yellow/Warning ≤ 8.03, Red/Severe > 8.03
• IgBert Full (Paired Concatenation Mode): Green/Good ≤ 9.36, Yellow/Warning ≤ 17.11, Red/Severe > 17.11
• IgBert FR (Paired Concatenation Mode): Green/Good ≤ 4.33, Yellow/Warning ≤ 10.32, Red/Severe > 10.32

Using the Tool

• Settings
  • Select Severe: Selects liability rows which are considered severe.
  • Hide Blank Entries: Hide entry rows which have no liabilities either before or after filtering.
  • Chain: Select the chain to display.
  • Region: Select the region to display.
  • Liabilities: Select the liabilities to display.
  • Language Model Cutoffs: Set separate cutoffs for AbLang, AbLang2, and IgBert to control which residue-level likelihood differences are displayed.

    Note: The liabilities in the grid after applying filtering are reflected in the downloads and structure view.

• Data Grid: Lists every detected liability (e.g., Deamidation sites, Unpaired Cysteines).
  • Start/End positions.
  • Severity Level (High/Med/Low).
  • Liability Type.
  • Positions that belong to the classic 30 Vernier zone residues (which may affect CDR conformation and antigen binding) are indicated with a (V) in the Region column.
• Engineering Mutation Designs: Click a liability to enter a mutation design used by the Engineering tab.
• Observations: Click a liability to enter an observation for that IMGT position. These are displayed in the Observations tab and on a clicked residue.
• 3D Viewer: If a PDB is associated, clicking Show 3D View will display the structure with frameworks, CDRs, and liabilities highlighted.
• Export
  • Export Grid: Exports the liabilities to an Excel file.
  • Export SVL: Exports the liabilities to SVL files, one for each entry, for use in the Molecular Operating Environment (MOE).
• Indicator Dots: Dots on a residue position indicate that there is an associated engineering design or observation at that position. Engineering mutations will appear as a small eggshell square while observations will appear as a small orange circle.

References

• The PDB structure viewer is provided by Mol*.
• Satlawa et al., "LAP: Liability Antibody Profiler by sequence & structural mapping of natural and therapeutic antibodies." PLOS Computational Biology (2024).